Find Reports
Select Report Type
Reimbursement Review
Displaying 676 - 700 of 1426
Please scroll or swipe to the right to view the full content.
| Title | Brand Name | Generic Name | Files | Therapeutic Area | Recommendation Type | Status | Submission Date | Recommendation Date Sort ascending | Project Number |
|---|---|---|---|---|---|---|---|---|---|
| Deferiprone | Ferriprox | Deferiprone | Transfusional iron overload | List with clinical criteria and/or conditions | Complete | SR0448-000 | |||
| Elvitegravir/cobicistat/emtric... | Genvoya | Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide | HIV infection | List | Complete | SR0449-000 | |||
| Sacubitril/valsartan | Entresto | Sacubitril/valsartan | Heart failure, NYHA class II or III | List with clinical criteria and/or conditions | Complete | SR0447-000 | |||
| Ombitasvir/ paritaprevir/ rito... | Technivie | Ombitasvir/ paritaprevir/ ritonavir | Hepatitis C, chronic | List with clinical criteria and/or conditions | Complete | SR0444-000 | |||
| Jakavi for Polycythemia Vera -... | Jakavi | Ruxolitinib | Polycythemia vera | Reimburse with clinical criteria and/or conditions | Complete | PC0065-000 | |||
| Denosumab (Drug Plan Submissi... | Xgeva | Denosumab (Drug Plan Submission) | Prevention of skeletal-related events due to bone metastases from breast cancer | List with clinical criteria and/or conditions | Complete | SR0433-000 | |||
| Tolvaptan | Jinarc | Tolvaptan | Autosomal dominant polycystic kidney disease | Do not list | Complete | SR0435-000 | |||
| Galsulfase (Drug Plan Submissi... | Naglazyme | Galsulfase (Drug Plan Submission) | Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome) | List with clinical criteria and/or conditions | Complete | SR0434-000 | |||
| Evolocumab | Repatha | Evolocumab | Primary hyperlipidemia; mixed dyslipidemia | List with clinical criteria and/or conditions | Complete | SR0441-000 | |||
| Fluticasone Furoate and Vilant... | Breo Ellipta | Fluticasone Furoate and Vilanterol (as trifenatate) | Asthma | List with clinical criteria and/or conditions | Complete | SR0442-000 | |||
| Apremilast | Otezla | Apremilast | Arthritis, psoriatic | List with criteria/condition | Complete | SR0437-000 | |||
| Fluticasone furoate | Arnuity Ellipta | Fluticasone furoate | Asthma | List with criteria/condition | Complete | SR0439-000 | |||
| Tiotropium / olodaterol | Inspiolto Respimat | Tiotropium / olodaterol | Chronic obstructive pulmonary disease | List with criteria/condition | Complete | SR0436-000 | |||
| Riociguat | Adempas | Riociguat | Pulmonary arterial hypertension (WHO group 1) | List with clinical criteria and/or conditions | Complete | SR0438-000 | |||
| Peginterferon beta-1a | Plegridy | Peginterferon beta-1a | Multiple sclerosis, relapsing-remitting | List with criteria/condition | Complete | SR0440-000 | |||
| Vectibix for mCRC – Details | Vectibix | Panitumumab | Metastatic Colorectal Cancer | Reimburse with clinical criteria and/or conditions | Complete | PC0060-000 | |||
| Revlimid for Newly Diagnosed M... | Revlimid | Lenalidomide | Multiple Myeloma, newly diagnosed | Reimburse with clinical criteria and/or conditions | Complete | PC0061-000 | |||
| Zykadia for Metastatic Non-Sma... | Zykadia | Ceritinib | Metastatic Non-Small Cell Lung Cancer | Do not reimburse | Complete | PC0062-000 | |||
| Dapagliflozin | Forxiga | Dapagliflozin | Diabetes mellitus, type 2 | List with clinical criteria and/or conditions | Complete | SR0428-000 | |||
| Ivermectin | Rosiver | Ivermectin | Rosacea | List with criteria/condition | Complete | SR0429-000 | |||
| Ivacaftor | Kalydeco | Ivacaftor | Cystic fibrosis, R117H CFTR gating mutation | List with criteria/condition | Complete | SR0430-000 | |||
| Rotigotine | Neupro | Rotigotine | Parkinson’s disease | List with clinical criteria and/or conditions | Complete | SR0432-000 | |||
| Keytruda for Metastatic Melano... | Keytruda | Pembrolizumab | Metastatic Melanoma | Reimburse with clinical criteria and/or conditions | Complete | PC0058-000 | |||
| Cyramza for Advanced GC or GEJ... | Cyramza | Ramucirumab | Metastatic Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma | Reimburse with clinical criteria and/or conditions | Complete | PC0059-000 | |||
| Secukinumab | Cosentyx | Secukinumab | Plaque psoriasis | List with criteria/condition | Complete | SR0407-000 |
Health Technology Review
Displaying 601 - 602 of 602
Horizon Scan
Displaying 101 - 110 of 110
Projects in Progress
Displaying 26 - 27 of 27
View All Reports
Displaying 676 - 700 of 2138
Please scroll or swipe to the right to view the full content.
| Title | Description | Files | Last Updated Sort ascending | Project Line | Project Sub Line | Status | Project Number |
|---|---|---|---|---|---|---|---|
| CADTH Pharmaceutical Reviews Update — Issue 35 | Reimbursement Review | Pharmaceutical Review Update | |||||
| Formulary Management of Biologics in Plaque Psoriasis | Health Technology Review | Technology Review | Completed | HD0011-000 | |||
| Living With Type 2 Diabetes | Health Technology Review | Technology Review | Completed | HC0045-000 | |||
| Tocilizumab for Neuromyelitis Optica Spectrum Disorder | Health Technology Review | Rapid Review | Completed | RC1477-000 | |||
| Canakinumab for Adult-Onset Still Disease | Health Technology Review | Rapid Review | Completed | RC1475-000 | |||
| ferumoxytol | Reimbursement Review | Withdrawn | SR0753-000 | ||||
| pembrolizumab | Reimbursement Review | Complete | PC0295-000 | ||||
| Formulary Management of Targeted Immune Modulators for Ulcerative Colitis: Environmental Scan | Health Technology Review | Environmental Scan | Completed | ES0366-000 | |||
| eptinezumab | Reimbursement Review | Complete | SR0743-000 | ||||
| Longevity of Partial and Complete Dentures | Health Technology Review | Rapid Review | Completed | RC1474-000 | |||
| pegvaliase | Reimbursement Review | Complete | SR0712-000 | ||||
| Dental Bridges for Partial Tooth Loss | Health Technology Review | Peer-reviewed Summary with Critical Appraisal | Completed | RD0068-000 | |||
| Policies for Pediatric Medicines | Health Technology Review | Environmental Scan | In Progress | ES0376-000 | |||
| Hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer | Reimbursement Review | Provisional Funding Algorithm | Complete | PH0018-000 | |||
| Automatic Stop Orders for Opioids | Health Technology Review | Rapid Review | Completed | RC1473-000 | |||
| Point-of-Care Tests for Pancreatitis | Horizon Scan | Health Technology Update | Completed | EN0045-000 | |||
| Dental Sealants for the Prevention of Dental Caries | Health Technology Review | Rapid Review | Completed | RC1471-000 | |||
| mepolizumab | Reimbursement Review | Complete | SR0735-000 | ||||
| guselkumab | Reimbursement Review | Complete | SR0733-000 | ||||
| edaravone | Reimbursement Review | Complete | SR0727-000 | ||||
| Nabilone for the Treatment of Post-Traumatic Stress Disorder: A 2023 Update | Health Technology Review | Summary with Critical Appraisal | Completed | RC1472-000 | |||
| dalbavancin | Reimbursement Review | Complete | SR0728-000 | ||||
| pitolisant hydrochloride | Reimbursement Review | Complete | SR0715-000 | ||||
| ozanimod | Reimbursement Review | Complete | SR0714-000 | ||||
| Bladder Scanners in Personal Care Homes | Health Technology Review | Rapid Review | Completed | RC1470-000 |
Provisional Funding Algorithm
Displaying 76 - 81 of 81